Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic Hypertrophy on Outcomes in Patients With Heart Failure

American Journal of Cardiology

Volumn 104, Issue 2, 2009, Pages 270-275

  Dhaliwal, Amandeep S ^a   Habib, Gabriel ^a   Deswal, Anita ^a,b   Verduzco, Melinda ^a   Souchek, Julianne ^a   Ramasubbu, Kumudha ^a,b   Aguilar, David ^b   Ma, Tony S ^a   Jneid, Hani M ^a   Bolos, Mariana ^b   Bozkurt, Biykem ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METOPROLOL; NITRATE; PRAZOSIN; SPIRONOLACTONE; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONFIDENCE INTERVALS; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME;

EID: 67649338464     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.030     Document Type: Article

References (29)

1. Colucci W.S., Wynne J., Holman B.L., and Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol 45 (1980) 337-344
2. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., and Flohr K.H. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
3. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 283 (2000) 1967-1975
4. Parra D., Lundy A.L., and Bierman B. Alpha-blocker monotherapy and anticipated occurrences of heart failure in hypertensive veterans. Am J Hypertens 18 (2005) 573-575
5. Messerli F.H. Doxazosin and congestive heart failure. J Am Coll Cardiol 38 (2001) 1295-1296
6. Stafford R.S., Furberg C.D., Finkelstein S.N., Cockburn I.M., Alehegn T., and Ma J. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 291 (2004) 54-62
7. Bryson C.L., Smith N.L., Kuller L.H., Chaves P.H., Manolio T.A., Lewis W., Boyko E.J., Furberg C.D., and Psaty B.M. Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists. J Am Geriatr Soc 52 (2004) 1648-1654
8. 1-adrenergic receptors in cardiac pathophysiology. Am Heart J 152 (2006) 842-850
9. Colucci W.S. Alpha-adrenergic receptor blockade with prazosin: consideration of hypertension, heart failure, and potential new applications. Ann Intern Med 97 (1982) 67-77
10. Markham Jr. R.V., Corbett J.R., Gilmore A., Pettinger W.A., and Firth B.G. Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. Am J Cardiol 51 (1983) 1346-1352
11. Bayliss J., Norell M.S., Canepa-Anson R., Reid C., Poole-Wilson P., and Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J Clin Res Ed 290 (1985) 1861-1865
12. Osborn J.L., DiBona G.F., and Thames M.D. Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther 216 (1981) 265-269
13. Dupont A.G. Effects of carvedilol on renal function. Eur J Clin Pharmacol 38 Suppl 2 (1990) S96-S100
14. Kukin M.L., Kalman J., Mannino M., Freudenberger R., Buchholz C., and Ocampo O. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol 77 (1996) 486-491
15. Stein L., Henry D.P., and Weinberger M.H. Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. Am J Med 70 (1981) 825-832
16. Colucci W.S., Williams G.H., and Braunwald E. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Ann Intern Med 93 (1980) 452-453
17. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., Billingham M.E., Harrison D.C., and Stinson E.B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
18. Stanek B., Frey B., Hulsmann M., Berger R., Sturm B., Strametz-Juranek J., Bergler-Klein J., Moser P., Bojic A., Hartter E., and Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442
19. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Ikram H., Sharpe N., Espiner E.A., Frampton C., Yandle T.G., and Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99 (1999) 786-792
20. 1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 116 (2006) 1005-1015
21. AUA guideline on management of benign prostatic hyperplasia (2003)-chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
22. Hamilton C.A., Reid J.L., and Vincent J. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit. Br J Pharmacol 86 (1985) 79-87
23. Louis W.J., McNeil J.J., Anavekar S.N., Conway E.L., Workman B., Howes L.G., Drummer O.H., and Jarrott B. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. J Cardiovasc Pharmacol 10 Suppl 12 (1987) S100-S103
24. Torvik D., and Madsbu H.P. Multicenter 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 21 Suppl 1 (1986) 69S-75S
25. Martin D.J., Lluel P., Guillot E., Coste A., Jammes D., and Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 282 (1997) 228-235
26. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., Torp-Pedersen C., Scherhag A., and Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
27. Weber K., Bohmeke T., van der Does R., and Taylor S.H. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 10 (1996) 113-117
28. Tham T.C., Guy S., McDermott B.J., Shanks R.G., and Riddell J.G. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol 40 (1995) 19-23
29. Tomlinson B., Bompart F., Graham B.R., Liu J.B., and Prichard B.N. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 36 Suppl 6 (1988) 37-47